168 related articles for article (PubMed ID: 30110192)
1. Successful maintenance therapy with apatinib inplatinum-resistant advanced ovarian cancer and literature review.
Jin M; Cai J; Wang X; Zhang T; Zhao Y
Cancer Biol Ther; 2018; 19(12):1088-1092. PubMed ID: 30110192
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment using apatinib with or without docetaxel in heavily pretreated advanced non-squamous non-small cell lung cancer: A case report and literature review.
Wu F; Zhang S; Gao G; Zhao J; Ren S; Zhou C
Cancer Biol Ther; 2018 Mar; 19(3):141-144. PubMed ID: 29261000
[TBL] [Abstract][Full Text] [Related]
3. Efficacy And Safety Of Apatinib Treatment In Platinum-Resistant Recurrent Epithelial Ovarian Cancer: A Real World Study.
Zhang J; Li A; Jiang Q; Zheng F; Zhu H
Drug Des Devel Ther; 2019; 13():3913-3918. PubMed ID: 31814710
[TBL] [Abstract][Full Text] [Related]
4. Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study.
Lan CY; Wang Y; Xiong Y; Li JD; Shen JX; Li YF; Zheng M; Zhang YN; Feng YL; Liu Q; Huang HQ; Huang X
Lancet Oncol; 2018 Sep; 19(9):1239-1246. PubMed ID: 30082170
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of apatinib in patients with recurrent epithelial ovarian cancer.
Miao M; Deng G; Luo S; Zhou J; Chen L; Yang J; He J; Li J; Yao J; Tan S; Tang J
Gynecol Oncol; 2018 Feb; 148(2):286-290. PubMed ID: 29248198
[TBL] [Abstract][Full Text] [Related]
6. Use of apatinib combined with pemetrexed for advanced ovarian cancer: A case report.
Sun H; Xiao M; Liu S; Shi R
Medicine (Baltimore); 2018 Jul; 97(27):e11036. PubMed ID: 29979376
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment of ovarian cancer with apatinib combined with chemotherapy: A case report.
Zhang M; Tian Z; Sun Y
Medicine (Baltimore); 2017 Nov; 96(45):e8570. PubMed ID: 29137078
[TBL] [Abstract][Full Text] [Related]
8. A new promising way of maintenance therapy in advanced ovarian cancer: a comparative clinical study.
Kiselev VI; Ashrafyan LA; Muyzhnek EL; Gerfanova EV; Antonova IB; Aleshikova OI; Sarkar FH
BMC Cancer; 2018 Sep; 18(1):904. PubMed ID: 30236079
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of low-dose apatinib in ovarian cancer patients with platinum-resistance or platinum-refractoriness: A single-center retrospective study.
Chen W; Li Z; Zheng Z; Wu X
Cancer Med; 2020 Aug; 9(16):5899-5907. PubMed ID: 32627959
[TBL] [Abstract][Full Text] [Related]
10. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
11. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
Li F; Zhu T; Cao B; Wang J; Liang L
Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
[TBL] [Abstract][Full Text] [Related]
12. Observation of the therapeutic effect of apatinib in advanced platinum-resistant recurrent epithelial ovarian cancer.
Pan Z; Luo Z; He H; Chen Y; Zhao B; Yang Z; Li L
J Ovarian Res; 2023 Feb; 16(1):44. PubMed ID: 36823642
[TBL] [Abstract][Full Text] [Related]
13. Adipose tissue area as a predictor for the efficacy of apatinib in platinum-resistant ovarian cancer: an exploratory imaging biomarker analysis of the AEROC trial.
Huang X; Xie C; Tang J; He W; Yang F; Tian W; Li J; Yang Q; Shen J; Xia L; Lan C
BMC Med; 2020 Oct; 18(1):267. PubMed ID: 33012286
[TBL] [Abstract][Full Text] [Related]
14. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
15. Response to apatinib in chemotherapy-failed advanced spindle cell breast carcinoma.
Zhou N; Liu C; Hou H; Zhang C; Liu D; Wang G; Liu K; Zhu J; Lv H; Li T; Zhang X
Oncotarget; 2016 Nov; 7(44):72373-72379. PubMed ID: 27738308
[TBL] [Abstract][Full Text] [Related]
16. Apatinib treatment combined with chemotherapy for advanced epithelial ovarian cancer: a case report.
Deng L; Wang Y; Lu W; Liu Q; Wu J; Jin J
Onco Targets Ther; 2017; 10():1521-1525. PubMed ID: 28352185
[TBL] [Abstract][Full Text] [Related]
17. Significant efficacy and well safety of apatinib in an advanced liver cancer patient: a case report and literature review.
Kou P; Zhang Y; Shao W; Zhu H; Zhang J; Wang H; Kong L; Yu J
Oncotarget; 2017 Mar; 8(12):20510-20515. PubMed ID: 28103584
[TBL] [Abstract][Full Text] [Related]
18. Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.
Li J; Qin S; Xu J; Xiong J; Wu C; Bai Y; Liu W; Tong J; Liu Y; Xu R; Wang Z; Wang Q; Ouyang X; Yang Y; Ba Y; Liang J; Lin X; Luo D; Zheng R; Wang X; Sun G; Wang L; Zheng L; Guo H; Wu J; Xu N; Yang J; Zhang H; Cheng Y; Wang N; Chen L; Fan Z; Sun P; Yu H
J Clin Oncol; 2016 May; 34(13):1448-54. PubMed ID: 26884585
[TBL] [Abstract][Full Text] [Related]
19. Apatinib plus paclitaxel versus paclitaxel monotherapy for platinum-resistant recurrent ovarian cancer treatment: A retrospective cohort study.
Geng A; Yang H; Wang Z; Wu C
J Clin Pharm Ther; 2022 Dec; 47(12):2264-2273. PubMed ID: 36404135
[TBL] [Abstract][Full Text] [Related]
20. Apatinib treatment efficiently delays biochemical-only recurrent ovarian cancer progression.
Wang Z; Huang Y; Long L; Zhou L; Huang Y; Gan L; Pu A; Li S; Xie R
J Ovarian Res; 2021 Jul; 14(1):91. PubMed ID: 34247630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
